Cytomegalovirus infection post-allogeneic stem cell transplant: Experience from a country with high seropositivity.

[1]  K. Fleischhauer,et al.  Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG , 2021, Blood advances.

[2]  C. Teng,et al.  Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation , 2021, Therapeutic advances in hematology.

[3]  B. Ko,et al.  Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. , 2021, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[4]  H. Nakasone,et al.  Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Einsele,et al.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. , 2020, Blood.

[6]  J. Kanda,et al.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. , 2020, Blood advances.

[7]  M. Hakki.  Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy , 2020, Current Hematologic Malignancy Reports.

[8]  Hong Liu,et al.  Pathogenesis of aplastic anemia , 2019, Hematology.

[9]  Stephanie J. Lee.  Classification systems for chronic graft-versus-host disease. , 2017, Blood.

[10]  F. Locatelli,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection , 2016, Expert review of hematology.

[11]  M. Norkin,et al.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. , 2016, Blood.

[12]  M. Robin,et al.  Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  K. Takenaka,et al.  Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related C , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  A. Raza,et al.  Sero-prevalence of Human Cytomegalovirus among blood donors in Lahore, Pakistan , 2015 .

[15]  C. Pannuti,et al.  Cytomegalovirus infection in transplant recipients , 2015, Clinics.

[16]  H. Hsiao,et al.  Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus , 2012, Annals of Hematology.

[17]  M. Boeckh,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients. , 2011, Hematology/oncology clinics of North America.

[18]  M. Cannon,et al.  Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection , 2010, Reviews in medical virology.

[19]  M. Cannon,et al.  Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  T. Chan,et al.  Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or CMV disease in cadaveric renal allograft recipients. , 2000, Transplantation proceedings.

[21]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.